108 related articles for article (PubMed ID: 28540758)
1. Treatment of hyperandrogenism in women with ethinylestradiol and cyproteroneacetate.
Mueck AO;
Eur J Contracept Reprod Health Care; 2017 Jun; 22(3):170-171. PubMed ID: 28540758
[No Abstract] [Full Text] [Related]
2. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
Leelaphiwat S; Jongwutiwes T; Lertvikool S; Tabcharoen C; Sukprasert M; Rattanasiri S; Weerakiet S
J Obstet Gynaecol Res; 2015 Mar; 41(3):402-10. PubMed ID: 25319761
[TBL] [Abstract][Full Text] [Related]
3. [Hormonal treatment effectivity in hyperandrogenic syndrome].
Visnovský J; Biringer K; Svecová I; Biringerová Z
Ceska Gynekol; 2010 Oct; 75(5):481-5. PubMed ID: 21374929
[TBL] [Abstract][Full Text] [Related]
4. Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women: the effect of cyproterone acetate-ethinyl estradiol treatment.
Luboshitzky R; Herer P; Shen-Orr Z
Exp Clin Endocrinol Diabetes; 2004 Feb; 112(2):102-7. PubMed ID: 15031776
[TBL] [Abstract][Full Text] [Related]
5. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy.
Franks S; Layton A; Glasier A
Hum Reprod; 2008 Feb; 23(2):231-2. PubMed ID: 18083746
[TBL] [Abstract][Full Text] [Related]
6. Effect of ethinylestradiol/cyproterone acetate on endothelial function in young non-obese women with polycystic ovary syndrome: a pilot study.
Naka KK; Kalantaridou SN; Bechlioulis A; Kravariti M; Kazakos N; Katsouras CS; Tsatsoulis A; Michalis LK
Gynecol Endocrinol; 2011 Sep; 27(9):615-21. PubMed ID: 21329419
[TBL] [Abstract][Full Text] [Related]
7. Treatment of androgen excess in adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin.
Ibáñez L; Diaz M; Sebastiani G; Sánchez-Infantes D; Salvador C; Lopez-Bermejo A; de Zegher F
J Clin Endocrinol Metab; 2011 Nov; 96(11):3361-6. PubMed ID: 21865363
[TBL] [Abstract][Full Text] [Related]
8. A randomized crossover study of medroxyprogesterone acetate and Diane-35 in adolescent girls with polycystic ovarian syndrome.
Chung JP; Yiu AK; Chung TK; Chan SS
J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):166-71. PubMed ID: 24656700
[TBL] [Abstract][Full Text] [Related]
9. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Ibáñez L; de Zegher F
J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
[TBL] [Abstract][Full Text] [Related]
10. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
[TBL] [Abstract][Full Text] [Related]
11. Prescribing of cyproterone acetate/ethinylestradiol in UK general practice: a retrospective descriptive study using The Health Improvement Network.
Cea Soriano L; Asiimwe A; García Rodriguez LA
Contraception; 2017 Mar; 95(3):299-305. PubMed ID: 27769766
[TBL] [Abstract][Full Text] [Related]
12. Treatment of female hyperandrogenism: estroprogestinic therapy at low dose in an inversal sequential scheme.
Ragonesi FP; Lo Mastro F; Arena V; Ermini M
Acta Eur Fertil; 1995; 26(4):141-3. PubMed ID: 9098476
[TBL] [Abstract][Full Text] [Related]
13. The effect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome.
Gul OB; Somunkiran A; Yucel O; Demirci F; Ozdemir I
Arch Gynecol Obstet; 2008 Jan; 277(1):25-30. PubMed ID: 17618446
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial.
Kahraman K; Sükür YE; Atabekoğlu CS; Ateş C; Taşkın S; Cetinkaya SE; Tolunay HE; Ozmen B; Sönmezer M; Berker B
Arch Gynecol Obstet; 2014 Aug; 290(2):321-8. PubMed ID: 24676694
[TBL] [Abstract][Full Text] [Related]
15. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
[TBL] [Abstract][Full Text] [Related]
16. How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?
Kabil Kucur S; Gozukara I; Aksoy A; Uludag EU; Keskin H; Kamalak Z; Carlioglu A
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):862-5. PubMed ID: 25402193
[TBL] [Abstract][Full Text] [Related]
17. Oral contraception vs insulin sensitization for 18 months in nonobese adolescents with androgen excess: posttreatment differences in C-reactive protein, intima-media thickness, visceral adiposity, insulin sensitivity, and menstrual regularity.
Ibáñez L; Díaz M; Sebastiani G; Marcos MV; López-Bermejo A; de Zegher F
J Clin Endocrinol Metab; 2013 May; 98(5):E902-7. PubMed ID: 23547047
[TBL] [Abstract][Full Text] [Related]
18. Effects of ethinylestradiol-cyproterone acetate vs. pioglitazone-flutamide-metformin on plasma FGF21 levels in adolescent girls with androgen excess.
Díaz M; Gallego-Escuredo JM; de Zegher F; Villarroya F; Ibáñez L
Diabetes Metab; 2016 Jun; 42(3):196-9. PubMed ID: 26546387
[No Abstract] [Full Text] [Related]
19. Polycystic ovary syndrome.
Al-Inany H
Clin Evid; 2004 Dec; (12):2678-88. PubMed ID: 15865813
[No Abstract] [Full Text] [Related]
20. Development of diabetes mellitus and hypertension due to aggravation of insulin resistance after estrogen--progestogen in HAIR-AN syndrome.
Vaidya RA; Shringi MS; Vaidya AB; Gogate JG
J Assoc Physicians India; 1997 Nov; 45(11):883-4. PubMed ID: 11229194
[No Abstract] [Full Text] [Related]
[Next] [New Search]
